Puma Biotechnology (PBYI) Raw Materials (2020 - 2026)
Puma Biotechnology's (PBYI) quarterly Raw Materials came in at $6.0 million in Q1 2026, down 15.77% YoY from $7.1 million in Q1 2025, and up 86.74% on a QoQ basis from $3.2 million in Q4 2025.
Puma Biotechnology (PBYI) Raw Materials (2020 - 2026) Analysis & Trends
Puma Biotechnology (PBYI) has 7 years of Raw Materials data on file, last reported at $6.0 million in Q1 2026.
- Quarterly Raw Materials fell 15.77% year-over-year to $6.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.0 million (down 15.77% YoY) and the FY2025 annual result came in at $3.2 million, down 55.28% from the prior year.
- Raw Materials advanced to $6.0 million in Q1 2026, from $3.2 million in the prior quarter.
- In the past five years, Raw Materials ranged from a high of $7.2 million in Q4 2024 to a low of $211000.0 in Q3 2024.
- A 5-year average of $3.7 million and a median of $3.6 million in 2025 frame the typical range for Raw Materials.
- Annual changes were most pronounced in 2024 — Raw Materials tumbled 83.74% — and 2025, when it soared 1626.07%.
- Tracing PBYI's Raw Materials over 5 years: stood at $1.7 million in 2022, then soared by 239.07% to $5.7 million in 2023, then gained by 26.17% to $7.2 million in 2024, then sank by 55.28% to $3.2 million in 2025, then jumped by 86.74% to $6.0 million in 2026.
- The last three Raw Materials figures came in at $6.0 million (Q1 2026), $3.2 million (Q4 2025), and $3.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Puma Biotechnology | 451.24 Mn | 357.33 Mn | 44.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.48 Mn |
| Mar 31, 2026 | 6.00 Mn |
| Dec 31, 2025 | 3.21 Mn |
| Sep 30, 2025 | 3.64 Mn |
| Jun 30, 2025 | 6.50 Mn |
| Mar 31, 2025 | 7.12 Mn |
| Dec 31, 2024 | 7.18 Mn |
| Sep 30, 2024 | 211,000.00 |
| Jun 30, 2024 | 619,000.00 |
| Mar 31, 2024 | 4.50 Mn |
| Dec 31, 2023 | 5.69 Mn |
| Sep 30, 2023 | 1.27 Mn |
| Jun 30, 2023 | 3.81 Mn |
| Mar 31, 2023 | 1.68 Mn |
| Dec 31, 2022 | 1.68 Mn |
| Sep 30, 2022 | 2.03 Mn |
| Jun 30, 2022 | 2.90 Mn |
| Mar 31, 2022 | 4.04 Mn |
| Dec 31, 2021 | 4.57 Mn |
| Dec 31, 2020 | 1.43 Mn |